Merck tops earnings estimates on strong demand for Keytruda, new drugs even as HPV vaccine sales fall
The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...
Merck sees Gardasil China woes carrying into 2025
Merck & Co said on Thursday that weak sales of Gardasil in China are likely to carry over into 2025 as the vaccine's ...
FiercePharma10d
Gardasil's China troubles haunt Merck in Q3, with execs warning of more obstacles ahead
While Merck's oncology powerhouse Keytruda delivered another multibillion-dollar sales haul in the third quarter, regional ...
Merck: An Undervalued Dividend Machine
Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...
Merck Beats Q3 Estimates, But Lowers Annual Forecast As Gardasil Vaccine Hit By Low China Demand
Merck reports Q3 sales of $16.7 billion, up 4% year-over-year, with Keytruda revenue rising 17%. EPS beats estimates; 2024 guidance updated on global demand shifts.
NBC Chicago10d
Merck tops earnings estimates on strong demand for Keytruda, new drugs even as HPV vaccine sales fall
But Merck's vaccine that prevents cancer from HPV, the most common sexually transmitted infection in the U.S., posted another quarter of lighter-than-expected sales. But Merck's vaccine that ...
Merck's Gardasil Shot Challenges To Continue, Analysts Optimistic For Newly Approved Sotatercept For Rare Lung Disease
Merck's Q3 revenue rises, led by Keytruda's strong 17% YoY growth. Gardasil demand challenges in China impact sales, with ...